Family history of lung cancer in never smokers with non-small-cell lung cancer and its association with tumors harboring EGFR mutations

Lung Cancer

Volumn 79, Issue 3, 2013, Pages 193-197

  Gaughan, Elizabeth M ^a   Cryer, Sarah K ^a   Yeap, Beow Y ^b   Jackman, David M ^a   Costa, Daniel B ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

ALK; Anaplastic lymphoma kinase; EGFR; Epidermal growth factor receptor; Family history; KRAS; Lung cancer; Never smokers; Non small cell lung cancer

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR;

ADULT; ADVANCED CANCER; ARTICLE; FAMILY HISTORY; FEMALE; GENE MUTATION; GENOTYPE; HUMAN; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; ONCOGENE K RAS; PATHOGENESIS; PRIORITY JOURNAL;

CARCINOMA, NON-SMALL-CELL LUNG; DNA MUTATIONAL ANALYSIS; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; LUNG NEOPLASMS; MALE; MEDICAL HISTORY TAKING; MIDDLE AGED; MUTATION; RECEPTOR PROTEIN-TYROSINE KINASES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RETROSPECTIVE STUDIES; SMOKING;

EID: 84873151479     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2012.12.002     Document Type: Article

References (23)

1. Siegel R., Naishadham D., Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012, 62(1):10-29.
2. Sun S., Schiller J.H., Gazdar A.F. Lung cancer in never smokers-a different disease. Nat Rev Cancer 2007, 7(10):778-790.
3. Gaughan E.M., Costa D.B. Genotype-driven therapies for non-small cell lung cancer: focus on EGFR, KRAS and ALK gene abnormalities. Ther Adv Med Oncol 2011, 3(3):113-125.
4. Brennan P., Hainaut P., Boffetta P. Genetics of lung-cancer susceptibility. Lancet Oncol 2011, 12(4):399-408.
5. Cote M.L., Liu M., Bonassi S., Neri M., Schwartz A.G., Christiani D.C., et al. Increased risk of lung cancer in individuals with a family history of the disease: a pooled analysis from the International Lung Cancer Consortium. Eur J Cancer 2012, 48(13):1957-1968.
6. Brenner D.R., Hung R.J., Tsao M.S., Shepherd F.A., Johnston M.R., Narod S., et al. Lung cancer risk in never-smokers: a population-based case-control study of epidemiologic risk factors. BMC Cancer 2010, 10:285.
7. Nitadori J., Inoue M., Iwasaki M., Otani T., Sasazuki S., Nagai K., et al. Association between lung cancer incidence and family history of lung cancer: data from a large-scale population-based cohort study, the JPHC study. Chest 2006, 130(4):968-975.
8. Jackman D.M., Miller V.A., Cioffredi L.A., Yeap B.Y., Janne P.A., Riely G.J., et al. Impact of epidermal growth factor receptor and KRAS mutations on clinical outcomes in previously untreated non-small cell lung cancer patients: results of an online tumor registry of clinical trials. Clin Cancer Res 2009, 15(16):5267-5273.
9. Costa D.B., Nguyen K.S., Cho B.C., Sequist L.V., Jackman D.M., Riely G.J., et al. Effects of erlotinib in EGFR mutated non-small cell lung cancers with resistance to gefitinib. Clin Cancer Res 2008, 14(21):7060-7067.
10. Shaw A.T., Yeap B.Y., Mino-Kenudson M., Digumarthy S.R., Costa D.B., Heist R.S., et al. Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. J Clin Oncol 2009, 27(26):4247-4253.
11. Bailey-Wilson J.E., Amos C.I., Pinney S.M., Petersen G.M., de Andrade M., Wiest J.S., et al. A major lung cancer susceptibility locus maps to chromosome 6q23-25. Am J Hum Genet 2004, 75(3):460-474.
12. Li Y., Sheu C.C., Ye Y., de Andrade M., Wang L., Chang S.C., et al. Genetic variants and risk of lung cancer in never smokers: a genome-wide association study. Lancet Oncol 2010, 11(4):321-330.
13. Yasuda H., Figueiredo-Pontes L.L., Kobayashi S., Costa D.B. Preclinical rationale for use of the clinically available multitargeted tyrosine kinase inhibitor crizotinib in ROS1-translocated lung cancer. J Thorac Oncol 2012, 7(7):1086-1090.
14. Matsuo K., Ito H., Yatabe Y., Hiraki A., Hirose K., Wakai K., et al. Risk factors differ for non-small-cell lung cancers with and without EGFR mutation: assessment of smoking and sex by a case-control study in Japanese. Cancer Sci 2007, 98(1):96-101.
15. Kawaguchi T., Ando M., Kubo A., Takada M., Atagi S., Okishio K., et al. Long exposure of environmental tobacco smoke associated with activating EGFR mutations in never-smokers with non-small cell lung cancer. Clin Cancer Res 2011, 17(1):39-45.
16. Liu W., He L., Ramirez J., Krishnaswamy S., Kanteti R., Wang Y.C., Functional EGFR, et al. germline polymorphisms may confer risk for EGFR somatic mutations in non-small cell lung cancer, with a predominant effect on exon 19 microdeletions. Cancer Res 2011, 71(7):2423-2427.
17. Bell D.W., Gore I., Okimoto R.A., Godin-Heymann N., Sordella R., Mulloy R., et al. Inherited susceptibility to lung cancer may be associated with the T790M drug resistance mutation in EGFR. Nat Genet 2005, 37(12):1315-1316.
18. Oxnard G.R., Miller V.A., Robson M.E., Azzoli C.G., Pao W., Ladanyi M., et al. Screening for germline EGFR T790M mutations through lung cancer genotyping. J Thorac Oncol 2012, 7(6):1049-1052.
19. Vikis H., Sato M., James M., Wang D., Wang Y., Wang M., et al. EGFR-T790M is a rare lung cancer susceptibility allele with enhanced kinase activity. Cancer Res 2007, 67(10):4665-4670.
20. Girard N., Lou E., Azzoli C.G., Reddy R., Robson M., Harlan M., et al. Analysis of genetic variants in never-smokers with lung cancer facilitated by an Internet-based blood collection protocol: a preliminary report. Clin Cancer Res 2010, 16(2):755-763.
21. Pennell N.A., Yin L., Keshtgarpour M., Ma P.C. Two generations of light/never-smokers with advanced adenocarcinoma of the lung with durable responses to erlotinib. J Thorac Oncol 2012, 7(7):1200-1201.
22. Couraud S., Zalcman G., Milleron B., Morin F., Souquet P.J. Lung cancer in never smokers-a review. Eur J Cancer 2012, 48(9):1299-1311.
23. Lissowska J., Foretova L., Dabek J., Zaridze D., Szeszenia-Dabrowska N., Rudnai P., et al. Family history and lung cancer risk: international multicentre case-control study in Eastern and Central Europe and meta-analyses. Cancer Causes Control 2010, 21(7):1091-1104.